DR ANTHONY MELVIN CRASTO,WorldDrugTracker, helping millions, A 90 % paralysed man in action for you, I am suffering from transverse mylitis and bound to a wheel chair, With death on the horizon, nothing will not stop me except God................DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai) , INDIA 25Yrs Exp. in the feld of Organic Chemistry,Working for GLENMARK GENERICS at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.Million hits on google, world acclamation from industry, academia, drug authorities for websites, blogs and educational contribution

Saturday, 1 August 2015

BOCEPREVIR, Боцепревир ,بوسيبريفير , 波普瑞韦 Part 2/2

 [14C]-Boceprevir NMR spectra analysis, Chemical CAS NO. 394730-60-0 NMR spectral analysis, [14C]-Boceprevir H-NMR spectrum


……………………………………………………………….
EXTRAS,,,,,,,,,,see      http://www.allfordrugs.com/2015/08/02/boceprevir-%D0%B1%D0%BE%D1%86%D0%B5%D0%BF%D1%80%D0%B5%D0%B2%D0%B8%D1%80-%D8%A8%D9%88%D8%B3%D9%8A%D8%A8%D8%B1%D9%8A%D9%81%D9%8A%D8%B1-%E6%B3%A2%E6%99%AE%E7%91%9E%E9%9F%A6/





1H NMR GRAPH

 

NMR GRAPH

 


13c nmr







13 C NMR GRAPH

WILL BE UPDATED[14C]-Boceprevir NMR spectra analysis, Chemical CAS NO. 394730-60-0 NMR spectral analysis, [14C]-Boceprevir H-NMR spectrum

13C NMR PREDICT









[14C]-Boceprevir NMR spectra analysis, Chemical CAS NO. 394730-60-0 NMR spectral analysis, [14C]-Boceprevir C-NMR spectrum
WO2010138889A1*28 May 20102 Dec 2010Concert Pharmaceuticals, Inc.Peptides for the treatment of hcv infections
WO2011125006A2*31 Mar 201113 Oct 2011Pfizer Inc.Novel sultam compounds
US20110034705 *17 Dec 200810 Feb 2011Schering-Plough CorporationProcess For the Synthesis of 3- Amino-3-Cyclobuthylmethyl-2-Hydroxypropionamide or Salts Thereof
US818813714 Aug 200929 May 2012Avila Therapeutics, Inc.HCV protease inhibitors and uses thereof
US852476010 Apr 20123 Sep 2013Celgene Avilomics Research, Inc.HCV protease inhibitors and uses thereof
EP2704570A1 *2 May 201212 Mar 2014Merck Sharp & Dohme Corp.Drug substances, pharmeceutical compositions and methods for preparing the same
WO2014061034A1*17 Oct 201324 Apr 2014Msn Laboratories LimitedProcess for preparation of boceprevir and intermediates thereof

References

Bacon, B et al. (March 2011). “Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection”N Engl J Med. 364 (13): 1207–17.doi:10.1056/NEJMoa1009482PMC 3153125PMID 21449784.
SYSTEMATIC (IUPAC) NAME
(1R,5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2(S)-carboxamide
CLINICAL DATA
TRADE NAMESVictrelis
AHFS/DRUGS.COMConsumer Drug Information
MEDLINEPLUSa611039
LICENCE DATAUS FDA:link
  • US: X (Contraindicated)
Oral
PHARMACOKINETIC DATA
PROTEIN BINDING75% [1]
HALF-LIFE3.4 hours [1]
IDENTIFIERS
394730-60-0 Yes
J05AE12
PUBCHEMCID 10324367
CHEMSPIDER8499830 Yes
UNII89BT58KELH Yes
CHEMBLCHEMBL218394 Yes
NIAID CHEMDB398493
CHEMICAL DATA
FORMULAC27H45N5O5

see part 1 at.............http://orgspectroscopyint.blogspot.in/2015/08/boceprevir-part-22_1.html
////

No comments:

Post a Comment